Abstract:In psychiatric disorders, common and rare genetic variants cause widespread dysfunction of cells and their interactions, especially in the prefrontal cortex, giving rise to psychiatric symptoms. To better understand these processes, we traced the effects of common and rare genetics, and cumulative disease risk scores, to their molecular footprints in human cortical single-cell types. We demonstrated that examining gene expression at single-exon resolution is crucial for understanding the cortical dysregulation associated with diagnosis and genetic risk derived from common variants. We then used disease risk scores to identify a core set of genes that serve as a footprint of common and rare variants in the cortex. Pathways enriched in these genes included dopamine regulation, circadian entrainment, and hormone regulation. Single-nuclei-RNA-sequencing pinpointed these enriched genes to excitatory cortical neurons. This study highlights the importance of studying sub-gene-level genetic architecture to classify psychiatric disorders based on biology rather than symptomatology, to identify novel targets for treatment development. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233860/pdf/jove-20-914.pdf> ### Funding Statement The Victorian Brain Bank tissue collection was supported by the National Health and Medical Research Council (NHMRC; Australia; grant number 566967) and the Cooperative Research Centre (CRC) for Mental Health and the Operational Infrastructure Support from the Victorian State Government. The New South Wales Brain Tissue Resource Centre at the University of Sydney was supported by the University of Sydney. Research reported in this publication was supported by the National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number NIAAA012725-15. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. Dr Knauer-Arloth was supported by the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #28063). Dr Matosin was supported by an Al and Val Rosenstrauss Fellowship from the Rebecca L Cooper Medical Research Foundation and grants from the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #26486) and the Rebecca L. Cooper Medical Research Foundation (#PG2020645). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of the Victorian Institute of Forensic Medicine gave ethical approval for this work. Ethics committee/IRB of the Human Ethics Committee of Melbourne Health gave ethical approval for this work. Ethics committee/IRB of the Central Institute of Mental Health Mannheim gave ethical approval for this work. Ethics committee/IRB of the University Hospital Bonn gave ethical approval for this work. Ethics committee/IRB of the Human Research Ethics Committees at the University of Wollongong gave ethical approval for this work. Ethics committee/IRB of the Ludwig-Maximilians-Universitaet Muenchen gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Expression data of dataset 1 in the present study are available online at GEO (GSE208338) and the genotypes are available upon reasonable request to the authors. Genes altered by rare coding variants from SCHEMA exome sequencing results in dataset 2 are available online at https://schema.broadinstitute.org/downloads. snRNA-seq data of dataset 3 in the present study are available online at GEO (GSE205642). <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205642> <https://drive.google.com/drive/folders/1JRyThjCwb7JFE6LdQQiAHwXQZFIO2o0V?usp=sharing> <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208338> <https://schema.broadinstitute.org/downloads>

Correction: Urine metabolomic profiles of autism and autistic traits–A twin study

Urine metabolomic profiles of autism and autistic traits-A twin study

Erratum: Genetic analysis of Down syndrome-associated heart defects in mice (Human Genetics DOI: 10.1007/s00439-011-0980-2)

Correction: Machine learning encodes urine and serum metabolic patterns for autoimmune disease discrimination, classification and metabolic dysregulation analysis

Urinary Untargeted Metabolic Profile Differentiates Children with Autism from Their Unaffected Siblings

Correction: Corrigendum: Identification of novel PKD1 and PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease

Correction: Huang Et Al. A Next Generation Sequencing-Based Protocol for Screening of Variants of Concern in Autism Spectrum Disorder. Cells 2022, 11, 10

Variant-risk-exon interplay impacts circadian rhythm and dopamine signaling pathway in severe psychiatric disorders

Correction: Babiec et al. Alterations of Purinergic Receptors Levels and Their Involvement in the Glial Cell Morphology in a Pre-Clinical Model of Autism Spectrum Disorders. Brain Sci. 2023, 13, 1088

Retraction: Preliminary evaluation of a novel nine-biomarker profile for the prediction of autism spectrum disorder

Correction: Gurevitz, M.; Leisman, G. Factors in Infancy That May Predict Autism Spectrum Disorder. Brain Sci. 2023, 13, 1374

Unraveling the metabolomic architecture of autism in a large Danish population-based cohort

Untargeted urine metabolomics and machine learning provide potential metabolic signatures in children with autism spectrum disorder

Urinary proteome profiling for children with autism using data-independent acquisition proteomics

Comparison of the Metabolic Profiles in the Plasma and Urine Samples Between Autistic and Typically Developing Boys: A Preliminary Study

Correction to: Imaging features of immune-mediated genitourinary disease

Genetic Insights from a Molecular Pathway Analysis on Two Independent Samples of Autistic Patients

Corrigendum: Gut Microbiota Features in Young Children With Autism Spectrum Disorders

Corrigendum: The predictive validity of a Brain Care Score for dementia and stroke: data from the UK Biobank cohort

Corrigendum: Classification of autism spectrum disorder using electroencephalography in Chinese children: a cross- sectional retrospective study

Author Correction: Single-cell transcriptomic analysis of Alzheimer’s disease